Kedar Upadhye Appointed As Cfo Of Biocon Biologics

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Kedar Upadhye appointed as CFO of Biocon Biologics

ri-calendar-2-lineOct 19, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Bengaluru-based Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has named Kedar Upadhye as its new Chief Financial Officer (CFO). The current CFO, MB Chinappa, will transition to a strategic finance role within the Biocon Group, effective October 31, 2023.

 

MB Chinappa, who has been CFO since January 2020, played a crucial role in shaping business strategy and driving profitable growth. He secured over $500 million in Private Equity investment and was instrumental in the company’s $3 billion+ acquisition of Viatris’ global biosimilars business in 2022, along with establishing a strategic vaccines partnership with the Serum Institute of India.

 

Kedar Upadhye, with over 23 years of global leadership experience in corporate finance, strategy, accounting, and investor relations, will assume the role of CFO at Biocon Biologics. He has held key positions at reputed organizations like Cipla, Dr. Reddy’s, PepsiCo, and Thermax. Before joining Biocon Biologics, Kedar served as the Chief Financial Officer at ReNew Energy Global Plc, a NASDAQ-listed decarbonization and renewable energy company.

 

Kedar expressed his enthusiasm for joining Biocon Biologics at this pivotal juncture and looks forward to contributing to the company’s journey towards becoming a leading global biosimilars enterprise. He emphasized his commitment to fostering sustainable and profitable growth in the biosimilars sector.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions